title: [Comparisons of occurrence and curative effect of interstitial pneumonia after the related HLA-haploidentical and HLA-matched sibling peripheral blood hematopoietic stem cell transplantation].
abstract: OBJECTIVE
  To compare occurrence and curative effect of interstitial pneumonia (IP) of patients with malignant hematologic disease after related HLA-haploidentical peripheral blood stem cell transplantation without T-cell depletion (RHNT-PBSCT) and non T cell-depleted HLA-matched sibling peripheral blood stem cell transplantation (MSNT-PBSCT).
  
  
  METHODS
  109 patients with malignant hematologic disease as the research cases received RHNT-PBSCT from January 2006 to December 2014, which were compared with 125 patients treated with MSNT-PBSCT during the same period to determine the occurrence of IP and curative effect produced by ganciclovir and joint adrenal glucocorticoids.
  
  
  RESULTS
  The incidences of IP in RHNT-PBSCT and MSNT-PBSCT groups were 15.60%(17/109) and 13.60%(17/125) (P=0.150), respectively; both the effective rates were 76.47%(13/17) (P=0.536), the difference was not statistically significant. Single factor analysis showed that acute graft versus host disease was a risk factor for the occurrence of IP after RHNT-PBSCT (P=0.001).
  
  
  CONCLUSIONS
  The incidence of IP in patients with malignant hematologic disease after RHNT-PBSCT didn' t increase when compared with patients after MSNT-PBSCT. The curative effects of the two groups were equivalent after priority to ganciclovir and joint adrenal glucocorticoids.
authors.affiliation: Hematologic Disease Center, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region Research Institute of Hematology, Urumqi 830054, China.
authors.forename: X Y
authors.initials: XY
authors.lastname: Wang
authors.forename: M
authors.initials: M
authors.lastname: Jiang
authors.forename: J H
authors.initials: JH
authors.lastname: Qu
authors.forename: X L
authors.initials: XL
authors.lastname: Duan
authors.forename: H L
authors.initials: HL
authors.lastname: Yuan
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.forename: J L
authors.initials: JL
authors.lastname: Xu
authors.forename: L L
authors.initials: LL
authors.lastname: Ding
authors.forename: Crimea
authors.initials: C
authors.lastname: Nadia Abdul
authors.forename: L
authors.initials: L
authors.lastname: Li
authors.forename: Arsene
authors.initials: A
authors.lastname: Eed
authors.forename: X H
authors.initials: XH
authors.lastname: Guo
authors.forename: B Z
authors.initials: BZ
authors.lastname: Wen
mesh_terms: D015774:Ganciclovir / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000150:complications; D006402:Hematologic Diseases / Q000150:complications* / Q000628:therapy*; D006801:Humans; D015994:Incidence; D017563:Lung Diseases, Interstitial / Q000150:complications*; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D012307:Risk Factors; D035781:Siblings
chemical_list: D005938:Glucocorticoids; D015774:Ganciclovir